Huiqiang Zhang
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Development of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions.
Journal: Scientific reports
Published: March 17, 2025
Multi-omics insights into the roles of CCNB1, PLK1, and HPSE in breast cancer progression: implications for prognosis and immunotherapy.
Journal: Discover oncology
Published: January 01, 2025
A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival.
Journal: Heliyon
Published: October 23, 2023
A case report of low-dose apatinib in the treatment of advanced triple-negative breast cancer.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: May 29, 2023
TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.
TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: May 01, 2023
Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
Journal: The oncologist
Published: December 22, 2022
Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2+ breast cancer with brain metastasis: a retrospective cohort study.
Journal: Annals of translational medicine
Published: September 19, 2022
Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: September 13, 2022
An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer.
Journal: Frontiers in oncology
Published: June 11, 2022
JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial.
Journal: Annals of translational medicine
Published: November 09, 2019
Platform-independent approach for cancer detection from gene expression profiles of peripheral blood cells.
Journal: Briefings in bioinformatics
Published: December 11, 2018
Clinical efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2 positive metastatic breast cancer
Journal: Zhonghua yi xue za zhi
Published: December 30, 2015
Last Updated: 09/26/2026